ANI Pharmaceuticals (FRA:BSFA) Current Accrued Expense : €54.0 Mil (As of Mar. 2025)

View and export this data going back to 2004. Start your Free Trial

What is ANI Pharmaceuticals Current Accrued Expense?

ANI Pharmaceuticals's Current Accrued Expense for the quarter that ended in Mar. 2025 was €54.0 Mil.

ANI Pharmaceuticals's quarterly Current Accrued Expense increased from Sep. 2024 (€48.4 Mil) to Dec. 2024 (€52.6 Mil) and increased from Dec. 2024 (€52.6 Mil) to Mar. 2025 (€54.0 Mil).

ANI Pharmaceuticals's annual Current Accrued Expense increased from Dec. 2022 (€24.1 Mil) to Dec. 2023 (€31.2 Mil) and increased from Dec. 2023 (€31.2 Mil) to Dec. 2024 (€52.6 Mil).

ANI Pharmaceuticals Current Accrued Expense Historical Data

The historical data trend for ANI Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ANI Pharmaceuticals Current Accrued Expense Chart

ANI Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Current Accrued Expense

Get a 7-Day Free Trial

13.72

17.14

24.14

31.22

52.60

ANI Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Current Accrued Expense	Get a 7-Day Free Trial															29.82	36.79	48.44	52.60	54.01

ANI Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

ANI Pharmaceuticals Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of ANI Pharmaceuticals's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

ANI Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ANI Pharmaceuticals Inc (FRA:BSFA) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

ANIP:USA

Address

210 Main Street West, Baudette, MN, USA, 56623

Website

https://www.anipharmaceuticals.com

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

ANI Pharmaceuticals Headlines

No Headlines